Skip to main content
. 2024 Feb 26;9:17. doi: 10.1186/s41181-024-00244-4

Table 2.

Biodistribution at 1 h and 3 h Post-injection in Tumor-Bearing Micea

[211At]At-NpGT [125I]I-NpGT [18F]F-NpGT [125I]I-IMT
Time after Injection 1 h 3 h 1 h 3 h 1 h 3 h 1 h 3 h
Blood 1.39 ± 0.33 c 0.49 ± 0.09 1.86 ± 0.09 0.54 ± 0.27 1.91 ± 0.35 0.37 ± 0.10 1.22 ± 0.24f,g 0.22 ± 004e,f
Liver 8.09 ± 1.34 2.25 ± 0.55 8.09 ± 1.22 2.94 ± 1.63 7.28 ± 1.30 1.40 ± 0.53 0.80 ± 0.20f,g 0.14 ± 0.04e,f
Spleen 2.22 ± 0.58 0.94 ± 0.17b 2.30 ± 0.58 0.56 ± 0.24 2.36 ± 0.68 0.63 ± 0.20 1.01 ± 0.22f,e,g 0.16 ± 0.05e,f,g
Kidney 32.8 ± 5.23c 14.8 ± 3.41c 25.0 ± 4.25d 10.4 ± 4.42d 13.5 ± 3.58 4.06 ± 1.53 19.6 ± 3.37 2.34 ± 0.31e,f
Pancreas 16.6 ± 1.03b 3.33 ± 1.17 30.1 ± 3.05 7.36 ± 4.07 20.3 ± 4.20 8.54 ± 2.55 11.9 ± 4.48 f 0.56 ± 0.21f,g
Heart 1.09 ± 0.20 0.74 ± 0.73 1.36 ± 0.20 0.43 ± 0.18 1.16 ± 0.30 0.56 ± 0.11 1.12 ± 0.29 0.11 ± 0.03
Lung 2.46 ± 0.41c 1.59 ± 1.10 2.14 ± 0.37d 0.58 ± 0.22 1.89 ± 0.35 0.65 ± 0.17 1.00 ± 0.39 e, f 0.17 ± 0.03e
Muscle 0.95 ± 0.53 0.42 ± 0.07 0.96 ± 0.14 0.59 ± 0.27 0.48 ± 0.08 0.62 ± 0.48 1.10 ± 0.28 0.27 ± 0.09
Bone 0.81 ± 0.23 0.44 ± 0.12 1.14 ± 0.01 0.42 ± 0.16 0.83 ± 0.22 0.58 ± 0.42 0.87 ± 0.06 0.14 ± 0.02
Tumor 2.72 ± 0.63 0.86 ± 0.23c 2.97 ± 0.58 0.99 ± 0.37 2.95 ± 0.40 1.46 ± 0.33 2.07 ± 0.23 g 0.25 ± 0.03e,f,g
Tumor/Blood 2.02 ± 0.51 1.73 ± 0.26c 1.59 ± 0.28 1.98 ± 0.39d 1.56 ± 0.15 3.96 ± 0.26 1.74 ± 0.35 1.17 ± 0.31e,f,g
Intestine* 5.56 ± 0.77c 5.88 ± 0.98c 5.12 ± 1.23 7.89 ± 3.22d 4.07 ± 0.25 2.60 ± 0.21 1.67 ± 0.49e,f,g 0.85 ± 0.21f
Stomach* 1.03 ± 0.20 0.88 ± 0.28c 1.22 ± 0.62 0.65 ± 0.43 1.03 ± 0.52 0.19 ± 0.07 0.94 ± 0.36 0.61 ± 0.38
Neck* 0.09 ± 0.02 0.11 ± 0.03 0.03 ± 0.01 0.09 ± 0.03 0.02 ± 0.01 0.01 ± 0.00 0.35 ± 0.06e,f,g 0.54 ± 0.11e,f,g

aTissue radioactivity was expressed as %ID/g ± SD for each group (n = 5)

*Tissue radioactivity was expressed as %ID. Statistical analysis was performed using on-way ANOVA followed by Tukey’s test between [211At]At-NpGT and [125I]I-NpGT (b), [211At]At-NpGT and [18F]F-NpGT (c), [125I]I-NpGT and [18F]F-NpGT (d), [211At]At-NpGT and [125I]I-IMT (e), [125I]I-NpGT and [125I]-IMT (f), and [18F]F-NpGT and [125I]I-IMT (g)